TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

EYSUVIS

LOTEPREDNOL ETABONATE
Ophthalmology Approved 2020-10-26
1
Indication
--
Phase 3 Trials
5
Years on Market

Details

Status
Prescription
First Approved
2020-10-26
Routes
OPHTHALMIC
Dosage Forms
SUSPENSION/DROPS

Companies

Active Ingredient: LOTEPREDNOL ETABONATE

EYSUVIS Approval History

Loading approval history...

What EYSUVIS Treats

1 indications

EYSUVIS is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Dry Eye Disease
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EYSUVIS FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

EYSUVIS Patents & Exclusivity

Latest Patent: May 2033

Patents (17 active)

US11219596 Expires May 3, 2033
US11596599 Expires May 3, 2033
US10857096 Expires May 3, 2033
US10945948 Expires May 3, 2033
US10940108 Expires May 3, 2033
US9532955 Expires May 3, 2033
US9737491 Expires May 3, 2033
US9056057 Expires May 3, 2033
US9827191 Expires May 3, 2033
US10058511 Expires May 3, 2033
+ 7 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.